Shanghai MicuRx Pharmaceutical Co., Ltd. Class A
SSSE:6883734.89
CNY
-0.13
(-2.59%)
ISIN
CNE100005PX4
Return %
Stock
S&P 500
1Y
-36.66
14.20
3Y
-27.01
81.12
5Y
- -
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Zheng Yu Yuan
- Full Time Employees
- 166
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Shanghai China
- IPO Date
- Aug 5, 2022
- Website
- micurxchina.com
- Similar Companies
- Business
- Shanghai MicuRx Pharmaceutical Co., Ltd. is a commercial- and clinical-stage biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics for the treatment of infectious diseases, with a specialized focus on multi-drug resistant bacterial and fungal superbug infections. The company operates through two main business segments: Pharmaceutical Research and Development, and Pharmaceutical Commercialization. Its product portfolio and pipeline comprise Contezolid (MRX-I), an oral next-generation oxazolidinone antibacterial agent approved for complicated skin and soft tissue infections caused by multi-drug resistant Gram-positive pathogens such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE); Contezolid Acefosamil (MRX-4), an intravenous and oral water-soluble prodrug of contezolid developed for severe systemic Gram-positive infections, diabetic foot infections, and multi-drug resistant tuberculosis; MRX-8, a novel polymyxin derivative engineered to combat multidrug-resistant Gram-negative pathogens including carbapenem-resistant Enterobacteriaceae (CRE) and Pseudomonas aeruginosa with enhanced safety and reduced nephrotoxicity; and MRX-5, an investigational antifungal therapeutic targeting invasive fungal infections. In addition to anti-infectives, the company conducts drug discovery programs targeting non-infectious therapeutic areas, including kidney diseases. Shanghai MicuRx Pharmaceutical markets its approved medications to hospitals, medical centers, and specialized healthcare providers across China and pursues international clinical development programs across global territories. The company maintains dual operations spanning China and the United States, operating research, clinical, and commercial facilities via its headquarters and its wholly owned U.S. subsidiary, MicuRx Pharmaceuticals, Inc., based in Hayward, California. Founded in 2007, Shanghai MicuRx Pharmaceutical Co., Ltd. is headquartered in Shanghai, China. In recent company developments, the company achieved expanded commercial distribution and hospital penetration for its flagship drug Contezolid following ongoing inclusion and coverage under China's National Reimbursement Drug List (NRDL). The company also progressed international Phase III clinical trials for Contezolid Acefosamil (MRX-4) across multi-center global sites, advanced Phase I clinical development for its Gram-negative candidate MRX-8 in both China and the United States, and actively established strategic commercialization alliances, distribution agreements, and cross-border partnership negotiations to support the overseas licensing and expansion of its proprietary antimicrobial pipeline.